Contact Information: Contact: Rachel Levine Director Corporate Development & Communications Cleveland BioLabs, Inc. T: (646) 284-9439 E: rlevine@cbiolabs.com
Cleveland BioLabs to Postpone Year-End Update Conference Call
Business on Track to Achieve Objectives
| Source: Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwire - December 17, 2007) - Cleveland BioLabs, Inc. (NASDAQ : CBLI ) today
announced that it will postpone its year-end investor update conference
call.
Dr. Michael Fonstein, Chief Executive Officer and President of Cleveland
BioLabs, stated, "We achieved our milestones for the year and the business
is on track for 2008. We will reschedule our year-end update call."
About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a drug discovery and development company
leveraging its proprietary discoveries about programmed cell death to treat
cancer and protect normal tissues from exposure to radiation and other
stresses. The Company has strategic partnerships with the Cleveland
Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed
Forces Research Radiobiology Institute. To learn more about Cleveland
BioLabs, Inc., please visit the company's website at
http://www.cbiolabs.com.
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect management's current expectations, as of the date of
this press release, and involve certain risks and uncertainties. Our actual
results could differ materially from those anticipated in these
forward-looking statements as a result of various factors. Some of the
factors that could cause future results to materially differ from the
recent results or those projected in forward-looking statements include the
"Risk Factors" described in our periodic filings with the Securities and
Exchange Commission.